AstraZeneca plc (AZN) Stock Rating Reaffirmed by J P Morgan Chase & Co
AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reiterated by J P Morgan Chase & Co in a report issued on Thursday. They presently have a GBX 4,500 ($58.12) price target on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price objective suggests a potential downside of 4.65% from the stock’s previous close.
A number of other research analysts have also weighed in on AZN. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday, June 21st. Deutsche Bank AG dropped their price target on shares of AstraZeneca plc from GBX 5,700 ($73.61) to GBX 5,300 ($68.45) and set a “buy” rating on the stock in a research report on Thursday, August 3rd. HSBC Holdings plc set a GBX 4,100 ($52.95) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Tuesday, August 8th. Liberum Capital reissued a “buy” rating and set a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a research report on Monday, June 5th. Finally, Credit Suisse Group reissued a “neutral” rating and set a GBX 5,000 ($64.57) price target on shares of AstraZeneca plc in a research report on Monday, June 19th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 5,022.91 ($64.87).
Shares of AstraZeneca plc (LON:AZN) opened at 4719.50 on Thursday. The firm’s 50-day moving average is GBX 4,556.15 and its 200 day moving average is GBX 4,880.61. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The company’s market capitalization is GBX 59.75 billion.
In other news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.